News

While obstacles may persist with limited access for patients and researchers, technology can help with this cancer clinical trial paradox.

The possibility of a "no-deal" Brexit scenario would have severe repercussions for clinical trials not only in the UK, but the rest of Europe as well.

Becky Carpenter, Head of North America/Euro Operations at WuXi Clinical, a newly formed CRO, discusses the evolution of the mid-sized pharma and CRO space-and the level of support now needed for some of the smaller and more nimble customers.